Kane Biotech公司将其伤口凝胶配给BioStem技术公司, Kane Biotech shifts US distribution of its wound gel to BioStem Technologies to boost sales.

Kane Biotech已经改变其美国分销伙伴的抗微生物创伤凝胶(revvvetm),改成BioStem Technology公司。 Kane Biotech has changed its US distribution partner for its antimicrobial wound gel, revyvetm, to BioStem Technologies, Inc. 这一转变的目的是扩大BioStem的伤口护理产品供应,并增加Kane Biotech在美国的凝胶销售量。 This shift aims to expand BioStem's wound care product offerings and increase sales of Kane Biotech's gel in the US. 从现有经销商ProgenaCare Global LLC获得的许可证正在等待监管批准和董事会同意,目的是在60天内最后敲定协议。 The acquisition from current distributor ProgenaCare Global LLC is pending regulatory approvals and board consent, with a goal to finalize the agreement within 60 days.